HCPCS Level II Code Lookup

M

• M0075 Cellular therapy
• M0076 Prolotherapy
• M0100 Intragastric hypothermia using gastric freezing
• M0201 Administration of pneumococcal, influenza, hepatitis b, and/or covid-19 vaccine inside a patient's home; reported only once per individual home per date of service when such vaccine administration(s) are performed at the patient's home
• M0220 Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring Historical
• M0221 Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency Historical
• M0222 Intravenous injection, bebtelovimab, includes injection and post administration monitoring Historical
• M0223 Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency Historical
• M0224 Intravenous infusion, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, includes infusion and post administration monitoring
• M0231 Intravenous infusion, tocilizumabbavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, includes infusion and post administration monitoring, first dose
• M0232 Intravenous infusion, tocilizumabbavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, includes infusion and post administration monitoring, second dose
• M0233 Intravenous infusion, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose
• M0234 Intravenous infusion, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, second dose
• M0235 Intravenous infusion, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, not otherwise classified, first dose
• M0236 Intravenous infusion, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, not otherwise classified, second dose
• M0237 Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose
• M0238 Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, second dose
• M0239 Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring Historical
• M0240 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses Historical
• M0241 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses Historical
• M0243 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring Historical
• M0244 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency Historical
• M0245 Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring Historical
• M0246 Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the covid 19 public health emergency Historical
• M0247 Intravenous infusion, sotrovimab, includes infusion and post administration monitoring Historical
• M0248 Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency Historical
• M0249 Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose
• M0250 Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, second dose
• M0300 Iv chelation therapy (chemical endarterectomy)
• M0301 Fabric wrapping of abdominal aneurysm
• M1000 Pain screened as moderate to severe Historical
• M1001 Plan of care to address moderate to severe pain documented on or before the date of the second visit with a clinician Historical
• M1002 Plan of care for moderate to severe pain not documented on or before the date of the second visit with a clinician, reason not given Historical
• M1003 Tb screening performed and results interpreted within twelve months prior to initiation of first-time biologic and/or immune response modifier therapy
• M1004 Documentation of medical reason for not screening for tb or interpreting results (i.e., patient positive for tb and documentation of past treatment; patient who has recently completed a course of anti-tb therapy)
• M1005 Tb screening not performed or results not interpreted, reason not given
• M1006 Disease activity not assessed, reason not given
• M1007 >=50% of total number of a patient's outpatient ra encounters assessed
• M1008 <50% of total number of a patient's outpatient ra encounters assessed
• M1009 Discharge/discontinuation of the episode of care documented in the medical record
• M1010 Discharge/discontinuation of the episode of care documented in the medical record
• M1011 Discharge/discontinuation of the episode of care documented in the medical record
• M1012 Discharge/discontinuation of the episode of care documented in the medical record
• M1013 Discharge/discontinuation of the episode of care documented in the medical record
• M1014 Discharge/discontinuation of the episode of care documented in the medical record
• M1015 Discharge/discontinuation of the episode of care documented in the medical record Historical
• M1016 Female patients unable to bear children
• M1017 Patient admitted to palliative care services Historical
• M1018 Patients with an active diagnosis or history of cancer (except basal cell and squamous cell skin carcinoma), patients who are heavy tobacco smokers, lung cancer screening patients
• M1019 Adolescent patients 12 to 17 years of age with major depression or dysthymia who reached remission at twelve months as demonstrated by a twelve month (+/-60 days) phq-9 or phq-9m score of less than 5
• M1020 Adolescent patients 12 to 17 years of age with major depression or dysthymia who did not reach remission at twelve months as demonstrated by a twelve month (+/-60 days) phq-9 or phq-9m score of less than 5. either phq-9 or phq-9m score was not assessed or is greater than or equal to 5
• M1021 Patient had only urgent care visits during the performance period
• M1022 Patients who were in hospice at any time during the performance period Historical
• M1023 Adolescent patients 12 to 17 years of age with major depression or dysthymia who reached remission at six months as demonstrated by a six month (+/-60 days) phq-9 or phq-9m score of less than five Historical
• M1024 Adolescent patients 12 to 17 years of age with major depression or dysthymia who did not reach remission at six months as demonstrated by a six month (+/-60 days) phq-9 or phq-9m score of less than five. either phq-9 or phq-9m score was not assessed or is greater than or equal to five Historical
• M1025 Patients who were in hospice at any time during the performance period Historical
• M1026 Patients who were in hospice at any time during the performance period Historical
• M1027 Imaging of the head (ct or mri) was obtained
• M1028 Documentation of patients with primary headache diagnosis and imaging other than ct or mri obtained
• M1029 Imaging of the head (ct or mri) was not obtained, reason not given
• M1030 Patients with clinical indications for imaging of the head Historical
• M1031 Patients with no clinical indications for imaging of the head Historical
• M1032 Adults currently taking pharmacotherapy for oud
• M1033 Pharmacotherapy for oud initiated after june 30th of performance period Historical
• M1034 Adults who have at least 180 days of continuous pharmacotherapy with a medication prescribed for oud without a gap of more than seven days
• M1035 Adults who are deliberately phased out of medication assisted treatment (mat) prior to 180 days of continuous treatment
• M1036 Adults who have not had at least 180 days of continuous pharmacotherapy with a medication prescribed for oud without a gap of more than seven days
• M1037 Patients with a diagnosis of lumbar spine region cancer at the time of the procedure
• M1038 Patients with a diagnosis of lumbar spine region fracture at the time of the procedure
• M1039 Patients with a diagnosis of lumbar spine region infection at the time of the procedure
• M1040 Patients with a diagnosis of lumbar idiopathic or congenital scoliosis
• M1041 Patient had cancer, acute fracture or infection related to the lumbar spine or patient had neuromuscular, idiopathic or congenital lumbar scoliosis
• M1042 Functional status measurement with score was obtained utilizing the oswestry disability index (odi version 2.1a) patient reported outcome tool within three months preoperatively and at one year (9 to 15 months) postoperatively Historical
• M1043 Functional status was not measured by the oswestry disability index (odi version 2.1a) at one year (9 to 15 months) postoperatively
• M1044 Functional status was measured by the oswestry disability index (odi version 2.1a) patient reported outcome tool within three months preoperatively and at one year (9 to 15 months) postoperatively Historical
• M1045 Functional status measured by the oxford knee score (oks) at one year (9 to 15 months) postoperatively was greater than or equal to 37 or knee injury and osteoarthritis outcome score joint replacement (koos, jr.) was greater than or equal to 71
• M1046 Functional status measured by the oxford knee score (oks) at one year (9 to 15 months) postoperatively was less than 37 or the knee injury and osteoarthritis outcome score joint replacement (koos, jr.) was less than 71 postoperatively
• M1047 Functional status was measured by the oxford knee score (oks) patient reported outcome tool within three months preoperatively and at one year (9 to 15 months) postoperatively Historical
• M1048 Functional status measurement with score was obtained utilizing the oswestry disability index (odi version 2.1a) patient reported outcome tool within three months preoperatively and at three months (6 to 20 weeks) postoperatively Historical
• M1049 Functional status was not measured by the oswestry disability index (odi version 2.1a) at three months (6 - 20 weeks) postoperatively
• M1050 Functional status was measured by the oswestry disability index (odi version 2.1a) patient reported outcome tool within three months preoperatively and at three months (6 to 20 weeks) postoperatively Historical
• M1051 Patient had cancer, acute fracture or infection related to the lumbar spine or patient had neuromuscular, idiopathic or congenital lumbar scoliosis
• M1052 Leg pain was not measured by the visual analog scale (vas) or numeric pain scale at one year (9 to 15 months) postoperatively
• M1053 Leg pain was measured by the visual analog scale (vas) within three months preoperatively and at one year (9 to 15 months) postoperatively Historical
• M1054 Patient had only urgent care visits during the performance period
• M1055 Aspirin or another antiplatelet therapy used
• M1056 Prescribed anticoagulant medication during the performance period, history of gi bleeding, history of intracranial bleeding, bleeding disorder and specific provider documented reasons: allergy to aspirin or anti-platelets, use of non-steroidal anti-inflammatory agents, drug-drug interaction, uncontrolled hypertension > 180/110 mmhg or gastroesophageal reflux disease
• M1057 Aspirin or another antiplatelet therapy not used, reason not given
• M1058 Patient was a permanent nursing home resident at any time during the performance period
• M1059 Patient was in hospice or receiving palliative care at any time during the performance period
• M1060 Patient died prior to the end of the performance period
• M1061 Patient pregnancy Historical
• M1062 Patient immunocompromised Historical
• M1063 Patients receiving high doses of immunosuppressive therapy Historical
• M1064 Shingrix vaccine documented as administered or previously received Historical
• M1065 Shingrix vaccine was not administered for reasons documented by clinician (e.g. patient administered vaccine other than shingrix, patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) Historical
• M1066 Shingrix vaccine not documented as administered, reason not given Historical
• M1067 Hospice services for patient provided any time during the measurement period
• M1068 Adults who are not ambulatory
• M1069 Patient screened for future fall risk